Patrick Y. Wen

MathematicsMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 2%percentile

3.4Author DataRank

Indexed papers

7in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 7 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States

Neuro-Oncology(2022)10.1093/neuonc/noac198

Top 8%

2.8DataRank

Top 8%98 citations

Madison L Shoaf, Gino Cioffi, Kristin Waite, Carol Kruchko, Patrick Y. Wen +4 more

Papers

Driven by 93 papers — median percentile 0. Top paper: “Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas”.

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Neuro-Oncology(2008)10.1215/15228517-2007-062

N/A

15.6DataRank · unranked

421 citations

W. K. Alfred Yung, Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy, Lisa M. DeAngelis +14 more

Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

The Lancet Oncology(2020)10.1016/s1470-2045(20)30321-1

N/A

5.7DataRank · unranked

527 citations

Ulrik Lassen, Élena Elez, Antoîne Italiano, Giuseppe Curigliano, Milind Javle +14 more

Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0611

N/A

4.8DataRank · unranked

264 citations

Marta Peñas-Prado, Katherine B. Peters, Howard A. Burris, Elizabeth A. Maher, Filip Jankú +16 more

Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial

Nature Medicine(2023)10.1038/s41591-023-02321-8

N/A

4.1DataRank · unranked

307 citations

Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein +18 more

National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States

Neuro-Oncology(2022)10.1093/neuonc/noac198

Top 8%

2.8DataRank

Top 8%98 citations

Madison L Shoaf, Gino Cioffi, Kristin Waite, Carol Kruchko, Patrick Y. Wen +4 more

Combined immunotherapy with controlled interleukin-12 gene therapy and immune checkpoint blockade in recurrent glioblastoma: An open-label, multi-institutional phase I trial

Neuro-Oncology(2021)10.1093/neuonc/noab271

N/A

2.4DataRank · unranked

110 citations

Arnold B. Gelb, Clark C. Chen, Ganesh Rao, David A. Reardon, Patrick Y. Wen +19 more

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

Nature Medicine(2023)10.1038/s41591-023-02392-7

N/A

1.6DataRank · unranked

66 citations

Albert E. Kim, Anita Giobbie‐Hurder, Eudocia Q. Lee, Nancy U. Lin, Beth Overmoyer +28 more

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

Nature(2018)10.1038/s41586-018-0792-9

N/A

1.1DataRank · unranked

1412 citations

Jing Sun, Itay Tirosh, Nathan D. Mathewson, Shuqiang Li, Giacomo Oliveira +51 more

Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma

Journal of Neuro-Oncology(2023)10.1007/s11060-023-04456-7

N/A

1.0DataRank · unranked

33 citations

Benjamin M. Ellingson, Catalina Raymond, Jingwen Yao, Patrick Y. Wen, Manmeet S. Ahluwalia +9 more

The design and evaluation of hybrid controlled trials that leverage external data and randomization

Nature Communications(2022)10.1038/s41467-022-33192-1

N/A

1.0DataRank · unranked

34 citations

Sean Khozin, Bill Louv, Jacob Sands, Patrick Y. Wen, Rifaquat Rahman +4 more

Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma

Neuro-Oncology(2023)10.1093/neuonc/noad117

N/A

0.915DataRank · unranked

35 citations

Laura Palma, Isaiah Yim, Nayah Bullen, Yuqing Qiu, Hiranmayi Ravichandran +12 more

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Nature Communications(2024)10.1038/s41467-024-54326-7

N/A

0.730DataRank · unranked

37 citations

Lu Sun, Gilbert C. Youssef, Raymond Y. Huang, Gang Li, Jiyoon Kim +31 more

A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients

Neuro-Oncology(2024)10.1093/neuonc/noae142

Top 37%

0.530DataRank

Top 37%14 citations

Jennifer Cotter, Mehdi Touat, Jayne Vogelzang, Cecília Almeida e Sousa, Will Pisano +24 more

First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2009

N/A

0.419DataRank · unranked

7 citations

Isaac H. Solomon, Hiroshi Nakashima, Sean Lawler, Daniel Triggs, Abigail Zhang +15 more

A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma

Neuro-Oncology(2025)10.1093/neuonc/noaf079

N/A

0.394DataRank · unranked

9 citations

Andrea G. Manzanera, Caroline Duault, Edgar Gonzalez‐Kozlova, Lenika Lopez, Stuart A. Grossman +50 more

A multicenter, phase 1, Adult Brain Tumor Consortium trial of oral terameprocol for patients with recurrent high-grade glioma (GATOR)

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101630

N/A

0.327DataRank · unranked

5 citations

Ahmad Ozair, Michelle A. Rudek, Xiaobu Ye, Matthias Holdhoff, Frank S. Lieberman +11 more

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Neuro-Oncology(2023)10.1093/neuonc/noad236

N/A

0.323DataRank · unranked

6 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

Leveraging external data in the design and analysis of clinical trials in neuro-oncology

The Lancet Oncology(2021)10.1016/s1470-2045(21)00488-5

N/A

0DataRank · unranked

85 citations

Steffen Ventz, Jon McDunn, Bill Louv, Irmarie Reyes‐Rivera, Mei‐Yin C. Polley +14 more

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002459

N/A

0DataRank · unranked

83 citations

Stephen Bagley, Patrick Y. Wen, Michael Lim, Michael Platten, Howard Colman +16 more

Deep learning-based automatic tumor burden assessment of pediatric high-grade gliomas, medulloblastomas, and other leptomeningeal seeding tumors

Neuro-Oncology(2021)10.1093/neuonc/noab151

N/A

0DataRank · unranked

76 citations

Daniel D Kim, Jay Patel, Xiaowei Zeng, Jiaer Huang, Ken Chang +20 more

A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2225

N/A

0DataRank · unranked

71 citations

Patrick Y. Wen, Martin J. van den Bent, Scott R. Plotkin, Annemiek Walenkamp, Adam L. Green +13 more

The use of external control data for predictions and futility interim analyses in clinical trials

Neuro-Oncology(2021)10.1093/neuonc/noab141

N/A

0DataRank · unranked

45 citations

Leah A. Comment, Bill Louv, Rifaquat Rahman, Patrick Y. Wen, Brian M. Alexander +2 more

Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making

Neuro-Oncology(2021)10.1093/neuonc/noab282

N/A

0DataRank · unranked

30 citations

Gilbert C Youssef, Mehdi Touat, J. Bryan Iorgulescu, Sydney Whorral, Marie Allen +17 more

Multimodal platform for assessing drug distribution and response in clinical trials

Neuro-Oncology(2021)10.1093/neuonc/noab197

N/A

0DataRank · unranked

14 citations

Ishwar N. Kohale, Ziming Du, Ilya Korsunsky, Walid M. Abdelmoula, Yang Dai +23 more

Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2024

N/A

0DataRank · unranked

9 citations

Priya Kumthekar, Patrick Y. Wen, Frederick G. Barker, Anat Stemmer‐Rachamimov, Roberta L. Beauchamp +4 more

Evaluation of GM-CSF and AS01B adjuvants in a phase I/IIa trial of a therapeutic CMV vaccine (VBI-1901) against recurrent glioblastoma (GBM).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.2047

N/A

0DataRank · unranked

4 citations

David A. Reardon, Deborah Forst, Eudocia Q. Lee, Fábio M. Iwamoto, Francisco Díaz‐Mitoma +3 more

Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

Annals of Oncology(2022)10.1016/j.annonc.2021.12.014

N/A

0DataRank · unranked

349 citations

Robert J. Kreitman, Zev A. Wainberg, Y. Choi, Jan H.M. Schellens, Jean‐Charles Soria +9 more

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

Neuro-Oncology(2022)10.1093/neuonc/noac118

N/A

0DataRank · unranked

194 citations

Nayan Lamba, Manmeet S. Ahluwalia, Kenneth Aldape, Adrienne Boire, Priscilla K. Brastianos +20 more

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2664

N/A

0DataRank · unranked

96 citations

Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, Miguel Gil‐Gil, Vinay K. Puduvalli, Jeffrey J. Raizer +15 more

Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma

Nature Communications(2022)10.1038/s41467-022-32430-w

N/A

0DataRank · unranked

89 citations

Shu Wang, Sylwia A. Stopka, Jia‐Ren Lin, Clarence Yapp, Cecily C. Ritch +18 more

Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma

npj Precision Oncology(2022)10.1038/s41698-022-00304-5

N/A

0DataRank · unranked

81 citations

Betty Rouaisnel, Antoine Daina, Srivatsan Raghavan, Lauren A. Roller, Brandon M. Huffman +7 more

EANO - EURACAN - SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors

Neuro-Oncology(2022)10.1093/neuonc/noac188

N/A

0DataRank · unranked

70 citations

David Capper, Adam Waldman, Johan Pallud, Giuseppe Minniti, Thomas Kaley +15 more

Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-4064

N/A

0DataRank · unranked

44 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors

Neuro-Oncology(2022)10.1093/neuonc/noac086

N/A

0DataRank · unranked

23 citations

Elizabeth R. Gerstner, Andrew B. Lassman, Caroline Chung, Howard Colman, Patricia E. Cole +21 more

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13059

N/A

0DataRank · unranked

16 citations

Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire +22 more

DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis

Journal of Neuro-Oncology(2022)10.1007/s11060-022-03994-w

N/A

0DataRank · unranked

5 citations

Helen H. Shang, Chantel Cacciotti, Emily Everdell, Ayal A. Aizer, Rifaquat Rahman +11 more

Proceedings of the Survivorship Care in Neuro-Oncology Workshop sponsored by the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT)

Neuro-Oncology Advances(2022)10.1093/noajnl/vdac029

N/A

0DataRank · unranked

6 citations

Emily S. Tonorezos, Deborah K. Mayer, Marie Bakitas, Susan M. Chang, Mary E. Cooley +75 more

The predictive value of partialMGMTpromoter methylation for IDH-wild-type glioblastoma patients

Neuro-Oncology Practice(2022)10.1093/nop/npac070

N/A

0DataRank · unranked

6 citations

Patrick Y. Wen, J. Bryan Iorgulescu, Matthew Torre

Single Cell Spatial Analysis Reveals the Topology of Immunomodulatory Purinergic Signaling in Glioblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.01.12.475925

N/A

0DataRank · unranked

6 citations

Shu Wang, Sylwia A. Stopka, Jia‐Ren Lin, Rumana Rashid, Clarence Yapp +12 more

Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0131

N/A

0DataRank · unranked

154 citations

Abed Rahman Kawakibi, Sunjong Ji, Sebastian M. Waszak, Stefan R. Sweha, Mateus Mota +79 more

Liquid biopsy epigenomic profiling for cancer subtyping

Nature Medicine(2023)10.1038/s41591-023-02605-z

N/A

0DataRank · unranked

121 citations

Ji-Heui Seo, Matthew P. Davidsohn, Brad Fortunato, Karl Semaan, Shahabbedin Sotudian +38 more

Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours

Nature Reviews Clinical Oncology(2023)10.1038/s41571-023-00756-z

N/A

0DataRank · unranked

93 citations

Rupert Bartsch, Émilie Le Rhun, Anna S. Berghoff, Priscilla K. Brastianos, Javier Cortés +8 more

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

Nature Medicine(2023)10.1038/s41591-023-02464-8

N/A

0DataRank · unranked

54 citations

Kelly Hotchkiss, Ian F. Parney, John de Groot, Solmaz Sahebjam, Nader Sanai +31 more

Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival

Neuro-Oncology(2023)10.1093/neuonc/noad002

N/A

0DataRank · unranked

46 citations

Patrick Y. Wen, Susan M. Chang, Martin J. van den Bent, Michael A. Vogelbaum, Gang Li +11 more

Systematic characterization of antibody–drug conjugate targets in central nervous system tumors

Neuro-Oncology(2023)10.1093/neuonc/noad205

N/A

0DataRank · unranked

44 citations

Jong Suk Lee, Sabrina Chan, Terri Woo, Jacquelyn Jones, Sanda Alexandrescu +5 more

Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration

Frontiers in Radiology(2023)10.3389/fradi.2023.1267615

N/A

0DataRank · unranked

28 citations

Timothy J. Kaufmann, Timothy F. Cloughesy, Patrick Y. Wen, Benjamin M. Ellingson, Francesco Sanvito

Defining interventions and metrics to improve diversity in CNS clinical trial participation: A SNO and RANO effort

Neuro-Oncology(2023)10.1093/neuonc/noad242

N/A

0DataRank · unranked

22 citations

Ugonma Chukwueke, Sadhana Jackson, Eudocia Q. Lee, J Ricardo McFaline-Figueroa, Nicole E. Willmarth +9 more

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

The Lancet Oncology(2023)10.1016/s1470-2045(23)00005-0

N/A

0DataRank · unranked

26 citations

Mei‐Yin C. Polley, Laura Alder, Priscilla K. Brastianos, Carey K. Anders, Hussein A. Tawbi +9 more

Intratumoral drug-releasing microdevices allow in situ high-throughput pharmaco phenotyping in patients with gliomas

Science Translational Medicine(2023)10.1126/scitranslmed.adi0069

N/A

0DataRank · unranked

22 citations

Christine Dominas, Geoffrey Fell, Joshua D. Bernstock, Sarah E. Blitz, Debora Mazzetti +18 more

ALK Amplification and Rearrangements Are Recurrent Targetable Events in Congenital and Adult Glioblastoma

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-21-3521

N/A

0DataRank · unranked

19 citations

Ross Giglio, Maya Srikanth Graham, Guadalupe Garcia, Seth Malinowski, Jared K. Woods +41 more

Molecular Profiling in Neuro-Oncology: Where We Are, Where We're Heading, and How We Ensure Everyone Can Come Along

American Society of Clinical Oncology Educational Book(2023)10.1200/edbk_389322

N/A

0DataRank · unranked

19 citations

Patrick Y. Wen, Mei‐Yin C. Polley, Alyx B. Porter

Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3524

N/A

0DataRank · unranked

8 citations

Steffen Ventz, Robert Redd, Timothy F. Cloughesy, Brian M. Alexander, Patrick Y. Wen +2 more

Validation of Predictive Analyses for Interim Decisions in Clinical Trials

JCO Precision Oncology(2023)10.1200/po.22.00606

N/A

0DataRank · unranked

4 citations

Steffen Ventz, Andrea Arfè, Brian M. Alexander, Rifaquat Rahman, Patrick Y. Wen +2 more

Depth of radiographic response (DpR) and time to tumor regrowth (TTG) to predict overall survival following anti-VEGF therapy in recurrent glioblastoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2063

N/A

0DataRank · unranked

1 citations

Akifumi Hagiwara, Connor J. Morris, Nicholas S. Cho, Sonoko Oshima, Francesco Sanvito +12 more

Data from Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities

(2023)10.1158/0008-5472.c.6495155.v1

N/A

0DataRank · unranked

0 citations

Cameron Brennan, Patrick Y. Wen, Laura Durso, Keith L. Ligon, Aaron Richardson +9 more

Supplementary Table 4 from Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities

(2023)10.1158/0008-5472.22366478

Top 100%

0DataRank

Top 100%0 citations

Cameron Brennan, Patrick Y. Wen, Laura Durso, Keith L. Ligon, Aaron Richardson +9 more

Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6532395

Top 100%

0DataRank

Top 100%0 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Data from Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6532395.v1

Top 100%

0DataRank

Top 100%0 citations

Nathan Standifer, Jörg Dietrich, Jennifer Clarke, Gavin P. Dunn, Michael Lim +21 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168

Top 100%

0DataRank

Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Data from Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

(2023)10.1158/1078-0432.c.6530168.v1

Top 100%

0DataRank

Top 100%0 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.08.25.554868

N/A

0DataRank · unranked

0 citations

Kevin W Lou, Anita Giobbie‐Hurder, Ken Chang, Mishka Gidwani, Katharina Hoebel +38 more

Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions

Neuro-Oncology(2024)10.1093/neuonc/noae103

N/A

0DataRank · unranked

61 citations

Ugonma Chukwueke, Myung‐Ju Ahn, Ayal A. Aizer, Tejus Bale, Dieta Brandsma +24 more

Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendroglioma

Cancer Cell(2024)10.1016/j.ccell.2024.03.008

N/A

0DataRank · unranked

58 citations

Simon Gritsch, Masashi Nomura, Alexander Jucht, Jérôme Fortin, Ramya Raviram +25 more

Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastoma

Journal of Controlled Release(2024)10.1016/j.jconrel.2024.06.036

N/A

0DataRank · unranked

39 citations

Patrick Y. Wen, David A. Reardon, Stecia‐Marie Fletcher, Alexandra J. Golby, Nathan McDannold

A Neuroradiologist’s Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in Adults

American Journal of Neuroradiology(2024)10.3174/ajnr.a8396

N/A

0DataRank · unranked

34 citations

Francesco Sanvito, Timothy F. Cloughesy, Raymond Y. Huang, Javier Villanueva-Meyer, Whitney B. Pope +21 more

Non-Invasive Blood-Brain Barrier Disruption Using Acoustic Holography With a Clinical Focused Ultrasound System

IEEE Transactions on Biomedical Engineering(2024)10.1109/tbme.2024.3407678

N/A

0DataRank · unranked

12 citations

Yongzhi Zhang, Stecia‐Marie Fletcher, Patrick Y. Wen, David A. Reardon, Alexandra J. Golby +2 more

Enhancing neuro-oncology care through equity-driven applications of artificial intelligence

Neuro-Oncology(2024)10.1093/neuonc/noae127

N/A

0DataRank · unranked

10 citations

Youssef Sibih, Abraham Dada, Susan M. Chang, Patrick Y. Wen, Annette M. Molinaro +7 more

RANO 2.0 criteria: concepts applicable to the neuroradiologist's clinical practice

Current Opinion in Oncology(2024)10.1097/cco.0000000000001077

N/A

0DataRank · unranked

9 citations

Antonella Castellano, Timothy F. Cloughesy, Patrick Y. Wen, Benjamin M. Ellingson, Francesco Sanvito

CTNI-66. IDH-MUTANT GLIOMA PATIENTS TREATED WITH VORASIDENIB: ONGOING DATA FROM THE VORASIDENIB EXPANDED ACCESS PROGRAM

Neuro-Oncology(2024)10.1093/neuonc/noae165.0433

N/A

0DataRank · unranked

1 citations

Katherine B. Peters, Howard Colman, Jennie Taylor, Ingo K. Mellinghoff, Helen A. Shih +4 more

Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas

The Lancet Oncology(2025)10.1016/s1470-2045(25)00193-7

N/A

0DataRank · unranked

30 citations

Philipp Lohmann, Mariam Aboian, Ramon Barajas, William G. Breen, Jana Ivanidze +29 more

Response Assessment in Neuro-Oncology (RANO) 2009–2025: Broad scope and implementation—A progress report

Neuro-Oncology(2025)10.1093/neuonc/noaf118

N/A

0DataRank · unranked

8 citations

Michael A. Vogelbaum, Timothy F. Cloughesy, Norbert Galldiks, Nathalie L. Albert, Joerg-Christian Tonn +30 more

Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma

Current Oncology(2025)10.3390/curroncol32100541

N/A

0DataRank · unranked

4 citations

Kent C. Shih, Pierre Giglio, Howard Colman, Patrick Y. Wen, Jian Campian +6 more

Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma

Neuro-Oncology(2025)10.1093/neuonc/noaf287

N/A

0DataRank · unranked

4 citations

Elisa Aquilanti, Julie J. Miller, Zhou Lan, Aleksandra B Lasica, Isabel Arrillaga‐Romany +20 more

Informative censoring in externally controlled clinical trials: a potential source of bias

ESMO Open(2025)10.1016/j.esmoop.2024.104094

N/A

0DataRank · unranked

2 citations

David E. Schwartz, Rita Saha, Patrick Y. Wen, Rifaquat Rahman, Lorenzo Trippa +1 more

Establishing the content validity of patient-reported outcome measures used in neuro-oncology based on the WHO ICF framework: Part of the RANO-PRO initiative

Neuro-Oncology(2025)10.1093/neuonc/noaf108

N/A

0DataRank · unranked

0 citations

Linda Dirven, Tobias Walbert, Terri S. Armstrong, David Arons, Martin J. van den Bent +24 more

ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS

Neuro-Oncology(2018)10.1093/neuonc/noy148.027

N/A

0DataRank · unranked

0 citations

Itay Tirosh, Annabelle Anandappa, Jing Sun, Chang‐Jiun Wu, Evisa Gjini +21 more

Seizure characteristics and outcomes in patients with pleomorphic xanthoastrocytoma

Neuro-Oncology Advances(2025)10.1093/noajnl/vdaf134

N/A

0DataRank · unranked

0 citations

Colin A. Ellis, Kevin Xie, Nishant Sinha, Sharon X. Xie, Kathryn A. Davis +8 more

Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas

Neuro-Oncology(2020)10.1093/neuonc/noaa141

N/A

0DataRank · unranked

195 citations

C. Chad Quarles, Leland Hu, Bradley J. Erickson, Elizabeth R. Gerstner, Marion Smits +26 more

Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group

The Lancet Oncology(2020)10.1016/s1470-2045(20)30173-x

N/A

0DataRank · unranked

144 citations

Benita Tamrazi, Tina Young Poussaint, Sabine Mueller, Daddy Mata‐Mbemba, Enrico Franceschi +13 more

Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network(2020)10.6004/jnccn.2020.0052

N/A

0DataRank · unranked

570 citations

Jana Portnow, Manmeet S. Ahluwalia, Joachim M. Baehring, Henry Brem, Steven Brem +30 more

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-2500

N/A

0DataRank · unranked

259 citations

Annette M. Molinaro, Katherine B. Peters, Jennifer Clarke, Justin T. Jordan, John de Groot +17 more

Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report

The Lancet Oncology(2020)10.1016/s1470-2045(19)30796-x

N/A

0DataRank · unranked

81 citations

Linda Dirven, David Arons, Amanda Bates, Susan M. Chang, Corneel Coens +12 more

A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma

Neuro-Oncology(2020)10.1093/neuonc/noaa240

N/A

0DataRank · unranked

62 citations

Ying Yuan, Jimin Wu, Tito R. Mendoza, Elizabeth Vera, Antonio Omuro +9 more

Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment

Neuro-Oncology(2020)10.1093/neuonc/noaa105

N/A

0DataRank · unranked

52 citations

Robert J. Young, Benjamin M. Ellingson, Harini Veeraraghavan, Wei Wang, Florent Tixier +12 more

Evaluation of RAPNO criteria in medulloblastoma and other leptomeningeal seeding tumors using MRI and clinical data

Neuro-Oncology(2020)10.1093/neuonc/noaa072

N/A

0DataRank · unranked

22 citations

Hao Zhou, Oliver Y. Tang, Ken Chang, Panpan Wang, Xiaowei Zeng +14 more

Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa124

N/A

0DataRank · unranked

22 citations

John G. Kuhn, Kathleen R. Lamborn, Lauren E. Abrey, Lisa M. DeAngelis, Frank S. Lieberman +14 more

Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials

Neuro-Oncology(2020)10.1093/neuonc/noaa253

N/A

0DataRank · unranked

19 citations

Matthew S. Brown, Jerrold L. Boxerman, Elizabeth R. Gerstner, Timothy J. Kaufmann, Patricia E. Cole +10 more

Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Adult Medulloblastoma Workshop

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa097

N/A

0DataRank · unranked

14 citations

Brett Theeler, Brittany Cordeiro, Ira J. Dunkel, Peter Hau, Anita Mahajan +35 more

Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients

Neuro-Oncology(2020)10.1093/neuonc/noaa015

N/A

0DataRank · unranked

41 citations

Michael Weller, Joohee Sul, Stephen Bagley, Solmaz Sahebjam, Martin J. van den Bent +19 more

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas

Cell Reports(2020)10.1016/j.celrep.2020.108196

N/A

0DataRank · unranked

26 citations

Jing Ni, J Ricardo McFaline-Figueroa, Yanzhi Wang, Roderick T. Bronson, Keith L. Ligon +4 more

Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2568

N/A

0DataRank · unranked

6 citations

Brian M. Alexander, Nathalie Y.R. Agar, Manmeet S. Ahluwalia, Arati Desai, Jörg Dietrich +14 more

Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.2521

N/A

0DataRank · unranked

4 citations

Raymond Y. Huang, Javier Villanueva‐Meyer, Mary Jane Lim-Fat, Elizabeth George, Bryan Iorgulescu +13 more

Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3615

N/A

0DataRank · unranked

2 citations

Sylvia C. Kurz, Rohinton S. Tarapore, Ashley Sumrall, Nicholas Butowski, Rebecca A. Harrison +15 more

Patrick Y. Wen

Indexed papers

Top data-sharing exemplar

Papers